OMEROS CORP Deferred Tax Assets, Operating Loss Carryforwards
OMEROS CORP (OMER) had Deferred Tax Assets, Operating Loss Carryforwards of $91.71 million as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-31
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $91.71M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $80.41M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $95.18M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $85.89M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $91.71M 10-K · filed 2026-03-31 |
| 2024-12-31 | $80.41M 10-K · filed 2026-03-31 |
| 2023-12-31 | $95.18M 10-K · filed 2025-03-31 |
| 2022-12-31 | $85.89M 10-K · filed 2024-04-01 |
| 2021-12-31 | $143.66M 10-K · filed 2023-03-13 |
| 2020-12-31 | $149.99M 10-K · filed 2022-03-01 |
| 2019-12-31 | $126.79M 10-K · filed 2021-03-01 |
| 2018-12-31 | $113.93M 10-K · filed 2020-03-02 |
| 2017-12-31 | $90.50M 10-K · filed 2019-03-01 |
| 2016-12-31 | $126.41M 10-K · filed 2018-03-01 |
| 2015-12-31 | $110.09M 10-K · filed 2017-03-16 |
| 2014-12-31 | $88.40M 10-K · filed 2016-03-15 |
| 2013-12-31 | $68.94M 10-K · filed 2015-03-16 |
| 2012-12-31 | $59.12M 10-K · filed 2014-03-13 |
| 2011-12-31 | $48.90M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |